Cell cycle dependent antagonistic interactions between paclitaxel and carboplatin in combination therapy

Xiaoxiong Xiong, Meihua Sui, Weimin Fan, Andrew Kraft

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The combination of carboplatin and paclitaxel is widely used to treat multiple solid tumors including ovarian, lung and breast cancer. Usually these drugs are given simultaneously with little regard to the importance of scheduling to obtain a maximal response. To investigate the importance of sequencing, the human breast Bcap37 and ovarian OV2008 cancer cell lines were exposed to carboplatin and paclitaxel in three different sequences: (1) pretreatment with paclitaxel followed by carboplatin, (2) pretreatment of carboplatin followed by paclitaxel and (3) simultaneous treatment with these two agents. The combination of carboplatin and paclitaxel resulted in antagonistic interactions when tumor cells were exposed to carboplatin prior to paclitaxel or exposed to the two drugs simultaneously, but there was little antagonistic interaction observed when paclitaxel was administered before carboplatin. Biochemical examination revealed that pretreatment or cotreatment of carboplatin inhibited paclitaxel-induced IkBα degradation and bcl-2 phosphorylation. Further analyses demonstrated that carboplatin could significantly interfere with the cytotoxic effects of paclitaxel on both mitotic arrest and apoptotic cell death unless paclitaxel was administered before carboplatin. These results indicate that the interaction between paclitaxel and carboplatin is highly schedule dependent. The optimal schedule for this combination is sequential exposure of paclitaxel followed by carboplatin.

Original languageEnglish (US)
Pages (from-to)1067-1073
Number of pages7
JournalCancer Biology and Therapy
Volume6
Issue number7
StatePublished - Jul 2007
Externally publishedYes

Fingerprint

Carboplatin
Paclitaxel
Cell Cycle
Therapeutics
Ovarian Neoplasms
Appointments and Schedules
Pharmaceutical Preparations
Lung Neoplasms
Neoplasms
Breast
Cell Death
Phosphorylation
Breast Neoplasms

Keywords

  • Apoptosis
  • Cell cycle arrest
  • Combination therapy
  • Drug interaction
  • Paclitaxel

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cell cycle dependent antagonistic interactions between paclitaxel and carboplatin in combination therapy. / Xiong, Xiaoxiong; Sui, Meihua; Fan, Weimin; Kraft, Andrew.

In: Cancer Biology and Therapy, Vol. 6, No. 7, 07.2007, p. 1067-1073.

Research output: Contribution to journalArticle

@article{1f73a7a3e4b24c95b28af241ef24151d,
title = "Cell cycle dependent antagonistic interactions between paclitaxel and carboplatin in combination therapy",
abstract = "The combination of carboplatin and paclitaxel is widely used to treat multiple solid tumors including ovarian, lung and breast cancer. Usually these drugs are given simultaneously with little regard to the importance of scheduling to obtain a maximal response. To investigate the importance of sequencing, the human breast Bcap37 and ovarian OV2008 cancer cell lines were exposed to carboplatin and paclitaxel in three different sequences: (1) pretreatment with paclitaxel followed by carboplatin, (2) pretreatment of carboplatin followed by paclitaxel and (3) simultaneous treatment with these two agents. The combination of carboplatin and paclitaxel resulted in antagonistic interactions when tumor cells were exposed to carboplatin prior to paclitaxel or exposed to the two drugs simultaneously, but there was little antagonistic interaction observed when paclitaxel was administered before carboplatin. Biochemical examination revealed that pretreatment or cotreatment of carboplatin inhibited paclitaxel-induced IkBα degradation and bcl-2 phosphorylation. Further analyses demonstrated that carboplatin could significantly interfere with the cytotoxic effects of paclitaxel on both mitotic arrest and apoptotic cell death unless paclitaxel was administered before carboplatin. These results indicate that the interaction between paclitaxel and carboplatin is highly schedule dependent. The optimal schedule for this combination is sequential exposure of paclitaxel followed by carboplatin.",
keywords = "Apoptosis, Cell cycle arrest, Combination therapy, Drug interaction, Paclitaxel",
author = "Xiaoxiong Xiong and Meihua Sui and Weimin Fan and Andrew Kraft",
year = "2007",
month = "7",
language = "English (US)",
volume = "6",
pages = "1067--1073",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "7",

}

TY - JOUR

T1 - Cell cycle dependent antagonistic interactions between paclitaxel and carboplatin in combination therapy

AU - Xiong, Xiaoxiong

AU - Sui, Meihua

AU - Fan, Weimin

AU - Kraft, Andrew

PY - 2007/7

Y1 - 2007/7

N2 - The combination of carboplatin and paclitaxel is widely used to treat multiple solid tumors including ovarian, lung and breast cancer. Usually these drugs are given simultaneously with little regard to the importance of scheduling to obtain a maximal response. To investigate the importance of sequencing, the human breast Bcap37 and ovarian OV2008 cancer cell lines were exposed to carboplatin and paclitaxel in three different sequences: (1) pretreatment with paclitaxel followed by carboplatin, (2) pretreatment of carboplatin followed by paclitaxel and (3) simultaneous treatment with these two agents. The combination of carboplatin and paclitaxel resulted in antagonistic interactions when tumor cells were exposed to carboplatin prior to paclitaxel or exposed to the two drugs simultaneously, but there was little antagonistic interaction observed when paclitaxel was administered before carboplatin. Biochemical examination revealed that pretreatment or cotreatment of carboplatin inhibited paclitaxel-induced IkBα degradation and bcl-2 phosphorylation. Further analyses demonstrated that carboplatin could significantly interfere with the cytotoxic effects of paclitaxel on both mitotic arrest and apoptotic cell death unless paclitaxel was administered before carboplatin. These results indicate that the interaction between paclitaxel and carboplatin is highly schedule dependent. The optimal schedule for this combination is sequential exposure of paclitaxel followed by carboplatin.

AB - The combination of carboplatin and paclitaxel is widely used to treat multiple solid tumors including ovarian, lung and breast cancer. Usually these drugs are given simultaneously with little regard to the importance of scheduling to obtain a maximal response. To investigate the importance of sequencing, the human breast Bcap37 and ovarian OV2008 cancer cell lines were exposed to carboplatin and paclitaxel in three different sequences: (1) pretreatment with paclitaxel followed by carboplatin, (2) pretreatment of carboplatin followed by paclitaxel and (3) simultaneous treatment with these two agents. The combination of carboplatin and paclitaxel resulted in antagonistic interactions when tumor cells were exposed to carboplatin prior to paclitaxel or exposed to the two drugs simultaneously, but there was little antagonistic interaction observed when paclitaxel was administered before carboplatin. Biochemical examination revealed that pretreatment or cotreatment of carboplatin inhibited paclitaxel-induced IkBα degradation and bcl-2 phosphorylation. Further analyses demonstrated that carboplatin could significantly interfere with the cytotoxic effects of paclitaxel on both mitotic arrest and apoptotic cell death unless paclitaxel was administered before carboplatin. These results indicate that the interaction between paclitaxel and carboplatin is highly schedule dependent. The optimal schedule for this combination is sequential exposure of paclitaxel followed by carboplatin.

KW - Apoptosis

KW - Cell cycle arrest

KW - Combination therapy

KW - Drug interaction

KW - Paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=42449130976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42449130976&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 1067

EP - 1073

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 7

ER -